Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

@article{Katsuno2009LongtermTW,
  title={Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.},
  author={Kenji Katsuno and Yoshikazu Fujimori and Yukiko Ishikawa-Takemura and Masayuki Isaji},
  journal={European journal of pharmacology},
  year={2009},
  volume={618 1-3},
  pages={98-104}
}
Sergliflozin etabonate, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor, improves hyperglycemia by suppressing renal glucose reabsorption, in which SGLT2 participates as a dominant transporter. In the present study, we examined the antidiabetic profile of sergliflozin etabonate in a diabetic model, KK-A(y) mice, with symptoms of obesity and hyperinsulinemia. The blood glucose level was monitored in non-fasted female KK-A(y) mice after a single oral… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…